Brett Johnson

ORCID: 0000-0001-6810-551X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Genomics and Diagnostics
  • Glioma Diagnosis and Treatment
  • AI in cancer detection
  • Cell Image Analysis Techniques
  • Epigenetics and DNA Methylation
  • PARP inhibition in cancer therapy
  • Advanced Breast Cancer Therapies
  • Radiomics and Machine Learning in Medical Imaging
  • Single-cell and spatial transcriptomics
  • RNA modifications and cancer
  • Pancreatic and Hepatic Oncology Research
  • Cancer-related molecular mechanisms research
  • Genomics and Chromatin Dynamics
  • Cancer Immunotherapy and Biomarkers
  • Image Processing Techniques and Applications
  • Breast Cancer Treatment Studies
  • Advanced Biosensing Techniques and Applications
  • Culinary Culture and Tourism
  • Cancer Research and Treatments
  • Ferroptosis and cancer prognosis
  • Molecular Biology Techniques and Applications
  • Protein Degradation and Inhibitors
  • Lung Cancer Treatments and Mutations
  • Toxin Mechanisms and Immunotoxins
  • RNA and protein synthesis mechanisms

University of California, San Francisco
2010-2024

Oregon Health & Science University
2015-2024

Neurological Surgery
2013-2024

University of Massachusetts Chan Medical School
2024

UMass Memorial Medical Center
2024

The University of Texas MD Anderson Cancer Center
2023

Huntsman Cancer Institute
2016-2020

Dana-Farber Brigham Cancer Center
2020

Dana-Farber Cancer Institute
2020

Brigham and Women's Hospital
2020

Ewan Birney J Stamatoyannopoulos Anindya Dutta Roderic Guigó T Gingeras and 95 more Elliott H. Margulies Zhiping Weng M Snyder Emmanouil T. Dermitzakis Robert E. Thurman Michael S. Kuehn Christopher M. Taylor Shane Neph Christof Koch Saurabh Asthana Ankit Malhotra Ivan Adzhubei Jason Greenbaum Robert Andrews Paul Flicek Patrick J. Boyle Hua Cao N. P. Carter Gayle K. Clelland Sean Davis Nathan Day Pawandeep Dhami Shane C. Dillon Michael O. Dorschner Heike Fiegler Paul G. Giresi Jeff Goldy Michael Hawrylycz Andrew Haydock Richard Humbert Keith D. James Brett Johnson Ericka M. Johnson Tristan Frum Elizabeth Rosenzweig Neerja Karnani Kirsten Lee Grégory Lefebvre Patrick A. Navas Fidencio Neri Stephen C. J. Parker Peter J. Sabo Richard Sandstrom Anthony Shafer David Vetrie Molly Weaver Sarah Wilcox Man Yu Francis S. Collins Job Dekker Jason D. Lieb Thomas D. Tullius Gregory E. Crawford Shamil Sunyaev William Stafford Noble Ian Dunham Alexandre Reymond Philipp Kapranov Joel Rozowsky Deyou Zheng Robert Castelo Adam Frankish Jennifer Harrow Srinka Ghosh Albin Sandelin Ivo L. Hofacker Robert Baertsch Damian Keefe Sujit Dike Jill Cheng Heather A. Hirsch Edward A. Sekinger Julien Lagarde Josep F. Abril Atif Shahab Christoph Flamm Claudia Fried Jörg Hackermüller Jana Hertel Manja Lindemeyer Kristin Missal Andrea Tanzer Stefan Washietl Jan O. Korbel Olof Emanuelsson Jakob Skou Pedersen Nancy Holroyd Ruth Taylor David Swarbreck Nicholas Matthews Mark Dickson Daryl J. Thomas Matthew T. Weirauch James Gilbert Jörg Drenkow

10.1038/nature05874 article EN Nature 2007-06-01

Back with a Vengeance After surgery, gliomas (a type of brain tumor) recur in nearly all patients and often more aggressive form. Johnson et al. (p. 189 , published online 12 December 2013) used exome sequencing to explore whether recurrent tumors harbor different mutations than the primary mutational profile recurrences is influenced by postsurgical treatment temozolomide (TMZ), chemotherapeutic drug known damage DNA. In 40% cases, at least half initial glioma were undetected recurrence....

10.1126/science.1239947 article EN Science 2013-12-13

While the contentious politics (CP) model has come to dominate field of social movements, scholars note paradigm's shortcomings, especially its narrow focus on movement organizations, public protest, and political action. The conceptual wall between lifestyles movements created a theoretical blind spot at intersection private action participation, personal change, collective identity. We suggest that lifestyle (LMs) consciously actively promote lifestyle, or way life, as primary means foster...

10.1080/14742837.2012.640535 article EN Social movement studies 2012-01-01

Mechanisms of therapeutic resistance and vulnerability evolve in metastatic cancers as tumor cells extrinsic microenvironmental influences change during treatment. To support the development methods for identifying these mechanisms individual people, here we present an omic multidimensional spatial (OMS) atlas generated from four serial biopsies with breast cancer 3.5 years therapy. This resource links detailed, longitudinal clinical metadata that includes treatment times doses, anatomic...

10.1016/j.xcrm.2022.100525 article EN cc-by Cell Reports Medicine 2022-02-01

Tumor specimens contain a variety of healthy cells as well cancerous cells, and this heterogeneity underlies resistance to various cancer therapies. But problem has not been thoroughly investigated until recently. Meanwhile, technological breakthroughs in imaging have led an explosion molecular cellular profiling data from large numbers samples, modern machine learning approaches including deep shown produce encouraging results by finding hidden structures make accurate predictions. In...

10.1109/embc.2017.8036914 article EN 2017-07-01

Abstract Spatially-resolved molecular profiling by immunostaining tissue sections is a key feature in cancer diagnosis, subtyping, and treatment, where it complements routine histopathological evaluation clarifying tumor phenotypes. In this work, we present deep learning-based method called speedy histological-to-immunofluorescent translation (SHIFT) which takes histologic images of hematoxylin eosin (H&E)-stained as input, then near-real time returns inferred virtual immunofluorescence...

10.1038/s41598-020-74500-3 article EN cc-by Scientific Reports 2020-10-15

Abstract Objective This prospective multicenter multireader study evaluated the performance of 40% scan-time reduced spinal magnetic resonance imaging (MRI) reconstructed with deep learning (DL). Methods A total 61 patients underwent standard care (SOC) and accelerated (FAST) spine MRI. DL was used to enhance set (FAST-DL). Three neuroradiologists were presented paired side-by-side datasets (666 series). Datasets blinded randomized in sequence left-right display order. Image features...

10.1007/s00062-021-01121-2 article EN cc-by Clinical Neuroradiology 2021-11-30

In order to establish the workflows required implement a real-time process involving multi-omic analysis of patient samples support precision-guided therapeutic intervention, tissue acquisition and trial was implemented. This report describes our findings date, including frequency with which mutational testing led therapy outcome for those patients. Eligible patients presenting Oregon Health Science University Knight Cancer Institute were enrolled on study. Patients biopsy proven metastatic...

10.1186/s12967-018-1733-y article EN cc-by Journal of Translational Medicine 2018-12-01

Molecular heterogeneity in metastatic breast cancer presents multiple clinical challenges accurately characterizing and treating the disease. Current diagnostic approaches offer limited ability to assess that exists among lesions throughout treatment course. We developed a precision oncology platform combines serial biopsies, multi-omic analysis, longitudinal patient monitoring, molecular tumor boards, with goal of improving management through enhanced understanding entire ecosystem within...

10.1038/s41698-021-00165-4 article EN cc-by npj Precision Oncology 2021-03-26

In this paper, I use principles of civic education and social psychology to identify four main classroom contributors students' pessimistic appraisals their ability improve problems: authoritarian teaching methods, a culture “doom gloom,” little attention solutions problems, no linkage problems individual behavior. then propose five-step process effectively teach about while empowering students help solve these (1) the through which are constructed, (2) existence problem, (3) core causes (4)...

10.1177/0092055x0503300104 article EN Teaching Sociology 2005-01-01

Aberrant DNA hypomethylation may play an important role in the growth rate of glioblastoma (GBM), but functional impact on transcription remains poorly understood. We assayed GBM methylome with MeDIP-seq and MRE-seq, adjusting for copy number differences, a small set non-glioma CpG island methylator phenotype (non-G-CIMP) primary tumors. Recurrent hypomethylated loci were enriched within region chromosome 5p15 that is specified as cancer amplicon also encompasses TERT , encoding telomerase...

10.1101/gr.164707.113 article EN cc-by-nc Genome Research 2014-04-07

In a pilot study, we evaluated the feasibility of real-time deep analysis serial tumor samples from triple negative breast cancer patients to identify mechanisms resistance and treatment opportunities as they emerge under therapeutic stress engendered by poly-ADP-ribose polymerase (PARP) inhibitors (PARPi). BRCA-mutant basal exceptional long-term survivor, striking destruction was accompanied marked infiltration immune cells containing CD8 effector cells, consistent with pre-clinical...

10.1038/s41698-021-00232-w article EN cc-by npj Precision Oncology 2021-10-19

Tumors may contain billions of cells, including distinct malignant clones and nonmalignant cell types. Clarifying the evolutionary histories, prevalence, defining molecular features these cells is essential for improving clinical outcomes, since intratumoral heterogeneity provides fuel acquired resistance to targeted therapies. Here we present a statistically motivated strategy deconstructing through multiomic multiscale analysis serial tumor sections (MOMA). By combining deep sampling...

10.3390/cancers16132429 article EN Cancers 2024-07-01

2015 Background: PEX is an oral small molecule inhibitor of KIT and CSF1 receptor expressed on microglia, blood vessels, glioblastoma (GBM) tumor cells. achieved good tissue exposure in a prior recurrent GBM study, preclinical studies indicate may sensitize to standard care (SOC) therapy through effects both microenvironment. Methods: Phase Ib determined the recommended II dose (RP2D) with SOC XRT/TMZ. primary endpoint was progression free survival (PFS); secondary endpoints included overall...

10.1200/jco.2018.36.15_suppl.2015 article EN Journal of Clinical Oncology 2018-05-20

10.1023/b:quas.0000049267.29699.d9 article EN Qualitative Sociology 2004-01-01

Abstract Introduction There are no effective treatments for gliomas after progression on radiation, temozolomide, and bevacizumab. Microglia activation may be involved in radiation resistance can inhibited by the brain penetrating antibiotic minocycline. In this phase 1 trial, we examined safety effect survival, symptom burden, neurocognitive function of reirradiation, minocycline, Methods The trial used a 3 + design dose escalation followed ten person expansion. Patients received...

10.1007/s11060-020-03551-3 article EN cc-by Journal of Neuro-Oncology 2020-06-06

The cellular heterogeneity and complex tissue architecture of most tumor samples is a major obstacle in image analysis on standard hematoxylin eosin-stained (H&E) sections. A mixture cancer normal cells complicates the interpretation their cytological profiles. Furthermore, spatial arrangement architectural organization are generally not reflected characteristics analysis. To address these challenges, first we describe an automatic nuclei segmentation H&E In task deconvoluting heterogeneity,...

10.1109/embc.2016.7590914 article EN 2016-08-01

TPS1111 Background: There is an urgent need to develop novel non chemotherapy treatments for metastatic triple negative breast cancer (mTNBC) patients who otherwise have a poor prognosis. Immune checkpoint blockade (ICB) and PARP inhibitors (PARPi) independently shown promise the treatment of mTNBC, combination has early benefit in MEDIOLA TOPACIO trials. This trial looks 1) evaluate efficacy PARPi olaparib PD-L1 inhibitor durvalumab, 2) perform extensive multi-omics including protein based...

10.1200/jco.2019.37.15_suppl.tps1111 article EN Journal of Clinical Oncology 2019-05-20
Coming Soon ...